Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03198026
Title Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Cancer Center at Thomas Jefferson University
Indications

marginal zone B-cell lymphoma

follicular lymphoma

Therapies

Ibrutinib + Obinutuzumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.